O

Oncolys Biopharma Inc
TSE:4588

Watchlist Manager
Oncolys Biopharma Inc
TSE:4588
Watchlist
Price: 1 710 JPY 9.27% Market Closed
Market Cap: ¥48.9B

Operating Margin

-7 144.4%
Current
Declining
by 2 978.4%
vs 3-y average of -4 166%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-7 144.4%
=
Operating Income
¥-2B
/
Revenue
¥28.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-7 144.4%
=
Operating Income
¥-2B
/
Revenue
¥28.5m

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Oncolys Biopharma Inc
TSE:4588
48.9B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-7 144.4%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Oncolys Biopharma Inc
Glance View

Market Cap
48.9B JPY
Industry
Biotechnology

Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatments. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 33 full-time employees. The company went IPO on 2013-12-06. The firm operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The firm's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Oncolys Biopharma Inc Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-7 144.4%
=
Operating Income
¥-2B
/
Revenue
¥28.5m
What is Oncolys Biopharma Inc's current Operating Margin?

The current Operating Margin for Oncolys Biopharma Inc is -7 144.4%, which is below its 3-year median of -4 166%.

How has Operating Margin changed over time?

Over the last 3 years, Oncolys Biopharma Inc’s Operating Margin has decreased from -128.8% to -7 144.4%. During this period, it reached a low of -7 609.7% on Jun 30, 2025 and a high of -123.4% on Dec 31, 2022.

Back to Top